Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.

ABSTRACT: The use of vaccines for cancer therapy is a promising immunotherapeutic strategy that has been shown to be effective against various cancers. Vaccines directly target tumors but their efficacy against glioblastoma multiforme (GBM) remains unclear. Immunotyping that classifies tumor samples is considered to be a biomarker for immunotherapy. This study aimed to identify potential GBM antigens suitable for vaccine development and develop a tool to predict the response of GBM patients to vaccination based on the immunotype. Gene Expression Profiling Interactive Analysis (GEPIA) was applied to evaluate the expression profile of GBM antigens and their influence on clinical prognosis, while the cBioPortal program was utilized to integrate and analyze genetic alterations. The correlation between a

SUBMITTER: Lin H 

PROVIDER: S-EPMC8847306 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature